Digestive Health Research
NaTiV3 Study
Study Evaluating Long-Term Efficacy And Safety Of Lanifibranor In Adult Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis (Nash) And Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage Of Liver Fibrosis
AGE: 18+ years old
SEX AT BIRTH: All
SEX AT BIRTH: All
TYPE: Investigational Drug Study
CONDITION: NASH - Nonalcoholic Steatohepatitis
CONDITION: NASH - Nonalcoholic Steatohepatitis
HEALTHY PARTICIPANTS: No
LOCATION: UH Cleveland Medical Center
LOCATION: UH Cleveland Medical Center
Learn More
For more information, please contact the study coordinator, Antonio Levert at 216-286-7069 or complete the online form below.
Study Purpose
The purpose of this research study is to evaluate if the study investigational medication improves your liver tissue scars (fibrosis) and resolves NASH. The study will also evaluate on the long term if the study medication can delay the complications that can ultimately damage the liver function (NASH disease progression).
Who Can Participate
Participants 18 years and older with a diagnosis of NASH may be eligible for this study.
- STUDY20211389
- NCT04849728